Hypertrophic cardiomyopathy progressively worsens once symptoms appear. Sudden death and heart failure are the leading causes of death in hypertrophic cardiomyopathy. There is still no cure for hypertrophic cardiomyopathy, but most patients can have a life expectancy and quality of life equal to that of a normal person. Severe complications can be controlled with drugs and instruments (ICD). Stem cells, transgenic, currently have no place in the treatment of hypertrophic cardiomyopathy. Treatment aims: to improve cardiac function, relieve symptoms and prevent complications. Internal therapy to relieve symptoms: 1. β-blockers: more than 20 preparations to slow heart rate, reduce contractility, improve diastolic ventricular filling, reduce oxygen demand, and reduce the degree of exercise-induced obstruction. Side effects: fatigue, headache, nightmares, impotence, whose side effects are reversible with discontinuation of the drug. Beta-blockers that have been used clinically for the treatment of hypertrophic cardiomyopathy include: ponerolol, atenolol, nadolol, metoprolol. 2, verapamil: maximum amount of 480mg / d, mostly slow-release formulation, can be used in patients with hypertrophic cardiomyopathy combined with asthma, weaken myocardial contraction, improve ventricular filling, relieve myocardial ischemia. Side effects: constipation, hair loss. Verapamil has been reported to cause sudden death in patients with dyspnea and nocturnal bouts of dyspnea. Because verapamil can cause an increase in pulmonary artery pressure and an increase in outflow tract obstruction, it may be related to the vasodilating effect of verapamil. Contraindications to verapamil: resting left ventricular outflow tract obstruction (not used in obstructive cardiomyopathy); severe symptoms (reported to cause sudden death); infants and children (reported to cause sudden death); pulmonary hypertension. Other calcium antagonists with vasodilating effects, such as nifedipine, should be avoided, and there is little clinical experience with diltiazem in the treatment of hypertrophic cardiomyopathy. 3. Diisoproterenol: It is a class IA antiarrhythmic drug with paracrine varicosities. It is used for patients with left ventricular outflow tract obstruction, but beta-blockers and verapamil are ineffective. Diisoproterenol is currently the most powerful clinical drug to reduce the pressure difference in the left ventricular outflow tract. 1982 for the treatment of hypertrophic cardiomyopathy, 100-200 mg/, times, 3 times a day, to reduce the left ventricular outflow tract obstruction caused by systolic mitral antegrade motion (SAM) and outflow tract obstruction at rest. Side effects: dry mouth, dry eyes, dyspepsia, dyspareunia, and prolonged QT due to anticholinergic effects. Because diisoprimide accelerates atrioventricular node conduction, it can cause accelerated ventricular rate in atrial fibrillation. Patients with atrial fibrillation should use diisoprimide with beta-blockers to prevent excessive ventricular rate. The use of diisopramine in non-obstructive cardiomyopathy can reduce cardiac output and worsen symptoms. Clinical experience with sotalol in the treatment of hypertrophic cardiomyopathy is limited. Compounding contraindications: diisoproterenol + etanercept; diisoproterenol + sotalol; quinidine + isoproterenol; quinidine + procalcitonide. Peripheral vasodilators, increasing outflow tract obstruction, nitroglycerin, angiotensin converting enzyme inhibitors (ACEI) class, angiotensin II receptor antagonists (ARB) class, contraindicated in patients with outflow tract obstruction (rest or exercise induced). In patients with severe heart failure, etanercept should be less than 400 mg/d. Diuretics: are generally not used because dehydration aggravates obstructive symptoms and electrolyte disturbances lead to arrhythmias. Digitalis is usually contraindicated. Patients with hypertrophic cardiomyopathy are advised to avoid exertion, prevent respiratory infections, stop smoking and drinking, maintain a good state of mind, and regularly visit the hospital for review to protect or improve cardiac function and improve quality of life.